Brain tumor patients may get a survival boost from targeted drug combo
NCT ID NCT03212742
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olaparib, then checking if the combination helps patients live longer. About 91 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (a PARP inhibitor) combined with temozolomide chemotherapy and radiation therapy
What this could lead to
If successful, this combination could extend survival for patients with aggressive brain tumors that cannot be surgically removed.
What could go wrong
This is an early-phase trial (Phase I/IIa) with a small number of participants, so results may not apply broadly. The added drug may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH du Havre
Le Havre, France
-
CHU
Amiens, France
-
CHU
Bordeaux, France
-
Centre Eugène Marquis
Rennes, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Guillaume le Conquérant
Le Havre, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Centre léon Bérard
Lyon, France
-
GHBS
Lorient, France
-
Hôpitaux universitaires La Pitié Salpétrière - Charles Foix
Paris, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Paris, France
-
Institut de Cancérologie de l'Ouest
Angers, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France